Compare SLE & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | SHPH |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.2M |
| IPO Year | 2019 | 2022 |
| Metric | SLE | SHPH |
|---|---|---|
| Price | $4.25 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 14.3K | ★ 191.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,064,000.00 | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $49.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.10 | $0.12 |
| 52 Week High | $11.43 | $5.59 |
| Indicator | SLE | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 60.09 |
| Support Level | $4.02 | $0.80 |
| Resistance Level | $5.24 | $1.06 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 69.64 | 73.96 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.